The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatitis C virus therapeutic development: in pursuit of perfectovir
Dore GJ1, Feld JJ2. Clin Infect Dis. 2015 Mar 11. pii: civ197. [Epub ahead of print]
Author information
1Kirby Institute, UNSW Australia, Sydney, Australia St Vincent's Hospital, Sydney, Australia.
2Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto.
Abstract
The next decade will be a crucial period in the public health response to hepatitis C virus (HCV) infection. The rapid development of direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near optimal efficacy with well tolerated short duration all oral regimens. As the zenith in HCV therapeutic development approaches, there remain several key obstacles to the broad implementation of interferon-free DAA regimens. The extent of HCV screening and disease assessment, global and national public health prioritization, and drug pricing will determine the potential impact on disease burden derived from introduction of these exciting new HCV therapies. Public health partnerships and advocacy will be crucial to remove barriers to enhanced HCV treatment access.